Italia markets close in 7 hours 50 minutes

Intuitive Surgical, Inc. (ISRG)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
341,52+1,89 (+0,56%)
Alla chiusura: 4:00PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente339,63
Aperto339,75
Denaro0,00 x 800
Lettera0,00 x 1200
Min-Max giorno337,64 - 342,68
Intervallo di 52 settimane217,67 - 362,34
Volume1.318.992
Media Volume1.535.420
Capitalizzazione122,004B
Beta (5 anni mensile)1,07
Rapporto PE (ttm)73,64
EPS (ttm)4,64
Prossima data utili19 gen 2022 - 24 gen 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A353,77
  • GlobeNewswire

    Intuitive Announces Executive Leadership Changes

    Moves reflect growth and help advance minimally invasive careMarshall Mohr named new EVP for Global Business ServicesJamie Samath named CFODave Rosa named new Chief Strategy and Growth OfficerHenry Charlton named Chief Commercial Officer SUNNYVALE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced executive leadership changes that reflect the company’s growth and p

  • GlobeNewswire

    Intuitive Announces Third Quarter Earnings

    SUNNYVALE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2021. All share and per-share information have been retroactively adjusted to reflect a three-for-one stock split. Q3 Highlights Worldwide da Vinci procedures grew approximately 20% compared with the third quarter of 2020. The third qua

  • GlobeNewswire

    PRECIsE Clinical Study Preliminary Results Favorable for Intuitive’s Ion Endoluminal System for Peripheral Nodule Lung Biopsy

    SUNNYVALE, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the release of preliminary data from 69 subjects participating in the Prospective, Multi-Center Evaluation of the Clinical Utility (PRECIsE) – a post-market, multi-center clinical trial of its Ion endoluminal system. Use of the Ion system for pulmonary nodule biopsy resulted in an 83% diagnostic yield, wh